Fosamax (Alendronate Sodium) (No. II)

Fosamax (No. II), centered on claims that the osteoporosis drug alendronate sodium is linked to atypical femur fractures, carries a meaningfully sized pending-action count of 562 more than a decade after centralization — a profile consistent with a docket that has moved past its initial bellwether phase into an extended individual-resolution period rather than a docket approaching a single global settlement event. For a funder, that shape matters: rather than one settlement-fund calendar driving cash timing for the whole book, resolution is likely occurring on a rolling, claim-by-claim basis shaped by each plaintiff's fracture history, duration of alendronate use, and the strength of the causation record tying atypical fracture patterns to the drug rather than to underlying osteoporosis itself.

Inventory finance against a meaningful book of Fosamax II claims is a reasonable structure for a firm with real volume in this docket, but pricing needs to reflect the rolling-resolution profile rather than assuming a bulk settlement date. Diligence should focus on how a given firm's inventory is distributed across fracture severity, treatment duration, and causation-record strength, since atypical femur fracture claims vary considerably on the strength of the radiographic and epidemiological evidence tying a specific fracture pattern to prolonged bisphosphonate use.

Medical-lien considerations are substantial here — atypical femur fractures typically require surgical repair, extended recovery, and in some cases revision procedures, and lien exposure against expected recovery should be modeled explicitly rather than assumed to be a fixed percentage.

Given the rolling nature of resolution in this docket rather than a single fund-driven event, duration risk should be underwritten claim by claim within a portfolio rather than benchmarked to one docket-wide settlement date. Criterica Capital's mass-tort finance and medical-lien receivables products both apply here depending on where a specific claim sits in its lifecycle.

Criterica Intelligence's structural brief on this docket covers how causation proof for atypical fractures differs from more common bisphosphonate-related claims.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.